Treosulfan
- Generic Name
- Treosulfan
- Brand Names
- Trecondi
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14O8S2
- CAS Number
- 299-75-2
- Unique Ingredient Identifier
- CO61ER3EPI
- Background
Treosulfan is under investigation in Allogeneic Haematopoietic Stem Cell Transplantation. Treosulfan has been investigated for the treatment of Lymphoblastic Leukemia, Acute, Childhood.
- Indication
Not Available
- Associated Conditions
- -
- Associated Therapies
- HSCT conditioning therapy
Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2010-02-04
- Last Posted Date
- 2010-02-04
- Lead Sponsor
- medac GmbH
- Target Recruit Count
- 45
- Registration Number
- NCT01062490
- Locations
- 🇫🇮
Helsinki University Central Hospital, Helsinki, Finland
Study in Localized and Disseminated Ewing Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2009-10-01
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 907
- Registration Number
- NCT00987636
- Locations
- 🇩🇪
University Hopital Essen, Pediatrics III, Hematology/ Oncology, Sarcoma Centre, International Ewing Sarcoma Study Group, West German Cancer Centre, Essen, Germany
🇩🇪University Children´s Hospital, Pediatric Hematology and Oncology, Muenster, Germany
Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders
- Conditions
- Interventions
- Biological: Anti-Thymocyte GlobulinProcedure: Allogeneic Bone Marrow TransplantationDrug: CyclosporineDrug: Fludarabine PhosphateOther: Laboratory Biomarker AnalysisDrug: MethotrexateDrug: Mycophenolate MofetilProcedure: Peripheral Blood Stem Cell TransplantationRadiation: Total-Body IrradiationDrug: TacrolimusProcedure: Umbilical Cord Blood TransplantationDrug: Treosulfan
- First Posted Date
- 2009-06-12
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 98
- Registration Number
- NCT00919503
- Locations
- 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia
- Conditions
- Adult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Childhood Chronic Myelogenous LeukemiaAccelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With t(15;17)(q22;q12)Childhood Acute Lymphoblastic Leukemia in RemissionChildhood Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2009-03-12
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 96
- Registration Number
- NCT00860574
- Locations
- 🇺🇸
University of Colorado, Denver, Colorado, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
🇺🇸Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)
- Conditions
- Interventions
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- medac GmbH
- Target Recruit Count
- 570
- Registration Number
- NCT00822393
- Locations
- 🇮🇹
Ospedale Civile Pescara, Pescara, Italy
🇩🇪Universitätsklinikum Freiburg, Freiburg, Germany
🇩🇪Klinikum Nürnberg, 5. Medizinische Klinik, Nürnberg, Germany
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant
- Conditions
- Interventions
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 130
- Registration Number
- NCT00796068
- Locations
- 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸University of Colorado Hospital, Aurora, Colorado, United States
Treosulfan-based Conditioning for Transplantation in AML/MDS
- Conditions
- Interventions
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2015-12-02
- Lead Sponsor
- Dr. Avichai Shimoni MD
- Target Recruit Count
- 24
- Registration Number
- NCT00491634
- Locations
- 🇮🇱
Chaim Sheba Medical Center, Tel-Hashomer, Israel
Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2012-06-01
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 60
- Registration Number
- NCT00253513
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Preference Study With Elderly Patients Recurrent Ovarian Cancer
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2013-06-03
- Target Recruit Count
- 123
- Registration Number
- NCT00170690
- Locations
- 🇩🇪
Charité Campus Virchow-Klinikum, Berlin, Germany
Study of Metastatic Ocular Melanoma
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2007-08-31
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 48
- Registration Number
- NCT00168870
- Locations
- 🇩🇪
Hematology & Oncology Charité CBF Berlin, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.